Synlogic, Inc. (SYBX): R&D Expense
$43.0K
Year ended 2025-12-31
-90.6%
3-year compound annual growth
-75.4%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $43.0K | -99.5% | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | $9.15M | -79.2% | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | $43.97M | -15.5% | 2025-03-06, From 2023-01-01 |
| 2022-12-31 | $52.04M | +10.4% | 2024-03-19, From 2022-01-01 |
| 2021-12-31 | $47.13M | -0.7% | 2023-03-29, From 2021-01-01 |
| 2020-12-31 | $47.47M | +13.3% | 2022-03-17, From 2020-01-01 |
| 2019-12-31 | $41.91M | +10.2% | 2021-03-25, From 2019-01-01 |
| 2018-12-31 | $38.03M | +25.4% | 2020-03-12, From 2018-01-01 |
| 2017-12-31 | $30.34M | +102.1% | 2019-03-12, From 2017-01-01 |
| 2016-12-31 | $15.01M | n/c | 2018-03-20, From 2016-01-01 |
| 2015-12-31 | $18.95M | +79.7% | 2017-03-15, From 2015-01-01 |
| 2014-12-31 | $10.54M | +140.2% | 2017-03-15, From 2014-01-01 |
| 2013-12-31 | $4.39M | n/a | 2016-03-30, From 2013-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Synlogic, Inc. (SYBX) | 2025-12-31 | $43.0K | -99.5% |
| Abbott Laboratories (ABT) | 2025-12-31 | $2.94B | +3.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $9.95B | -10.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $13.34B | +21.3% |
| Pfizer Inc (PFE) | 2025-12-31 | $10.44B | -3.6% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $14.66B | -14.9% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $1.90M | +11.8% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $15.79B | -12.0% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $1.90M | -7.5% |
Compare SYBX, ABT, BMY, LLY side by side · Screen every company in Pharmaceutical Preparations ↗